Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224269 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis
A Early Phase 1 study, sponsored by University of Iowa.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT07224269 is a Early Phase 1 study that has not yet begun recruiting, run by University of Iowa. The registered enrollment target is 20 participants.
The verdict
NCT07224269, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Iowa.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This will be a single center, randomized, double-blind, placebo-controlled pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral sclerosis (ALS). The primary outcome of this study is to determine whether TZ increases adenosine triphosphate (ATP) levels in ALS. The investigators will measure adverse outcomes, safety, and tolerability of taking TZ. Procedures include blood draws, spirometry, fluorodeoxyglucose-positron emission tomography (FDG-PET) scans, questionnaires, and physical examinations. TZ will be titrated up to 5 mg PO daily. This is a pilot study and is not powered to assess efficacy of this medication. The investigators' hope is that this study will guide future studies of this (and similar) medications for the disease modification of ALS. This study also aims to learn more about how patients produce and use energy and if TZ can help to reverse energy deficits that appear in ALS.
Interventions
- DRUG Placebo
- DRUG Terazosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2027-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224269
The ClinicalTrials.gov registry entry for NCT07224269 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07224269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224269 about?
NCT07224269 is a clinical study titled "Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis". This will be a single center, randomized, double-blind, placebo-controlled pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral sclerosis (ALS). The primary outcome of this study is to determine whe...
What is the current status of trial NCT07224269?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-05-01. Estimated completion is 2027-05-31.
What interventions are being tested in trial NCT07224269?
The interventions under investigation include: Placebo (DRUG), Terazosine (DRUG).
Who is sponsoring clinical trial NCT07224269?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.